Gyre Therapeutics (GYRE) EBIT (2010 - 2026)

Gyre Therapeutics (GYRE) has reported EBIT for 17 consecutive years, with -$9.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 511.57% year-over-year to -$9.4 million; the TTM figure through Mar 2026 stood at -$141000.0 (down 101.36% YoY), while the FY2025 annual figure was $11.5 million, down 28.93% from the prior year.
• EBIT retreated to -$9.4 million in Q1 2026 per GYRE's latest filing, from $118000.0 in the prior quarter.
• Across five years, EBIT topped out at $51.5 million in Q2 2022 and bottomed at -$91.6 million in Q4 2023.
• Historically, EBIT has averaged -$2.3 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2022 — EBIT soared 358.76% — and 2026, when it sank 511.57%.
• Gyre Therapeutics' EBIT stood at -$22.5 million in 2022, then slumped by 307.98% to -$91.6 million in 2023, then surged by 100.73% to $665000.0 in 2024, then slumped by 82.26% to $118000.0 in 2025, then tumbled by 8027.97% to -$9.4 million in 2026.
• Business Quant data shows GYRE's EBIT at -$9.4 million in Q1 2026, $118000.0 in Q4 2025, and $6.9 million in Q3 2025.